

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The NCCN Guidelines recommend PET-adapted therapy for patients with advanced classical Hodgkin lymphoma (cHL) beginning treatment with ABVD: Patients receive 2 cycles of therapy and are then evaluated using PET/CT. Patients with a Deauville score of 1 to 3 then receive _____.

 - a. Four additional cycles of AVD
 - b. Dose-escalated BEACOPP
 - c. Either a or b
2. Patients on the control (ABVD) arm of the Phase III ECHELON-1 study evaluating brentuximab vedotin and AVD versus ABVD as front-line therapy for advanced-stage cHL received _____.

 - a. PET-adapted ABVD
 - b. Standard ABVD
 - c. Either regimen at the investigator's discretion
3. Results of the ECHELON-1 trial demonstrated the combination of brentuximab vedotin and AVD to be _____ to ABVD with regard to the primary endpoint of modified progression-free survival.

 - a. Equivalent
 - b. Inferior
 - c. Superior
4. Prophylaxis with growth factors lowered the risk of febrile neutropenia on the brentuximab vedotin and AVD arm in the ECHELON-1 trial.

 - a. True
 - b. False
5. Results of the Phase III AETHERA trial evaluating brentuximab vedotin versus placebo as consolidation therapy after autologous stem cell transplant in patients with HL at high risk of relapse demonstrated a statistically significant improvement in _____ with brentuximab vedotin.

 - a. Overall survival
 - b. Progression-free survival
 - c. Both a and b
 - d. Neither a nor b
6. Side effects of brentuximab vedotin include _____.

 - a. Febrile neutropenia
 - b. Peripheral neuropathy
 - c. Rash
 - d. All of the above
 - e. Both a and b
 - f. Both a and c
7. The combination of brentuximab vedotin and nivolumab _____ been demonstrated to be an active and well-tolerated salvage regimen for patients with relapsed/refractory HL.

 - a. Has
 - b. Has not
8. Which of the following statements is true regarding immune checkpoint inhibitors for the treatment of HL?

 - a. They elicit high overall response rates
 - b. Remissions are typically not durable
 - c. Both a and b

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. Results of the Phase II BREACH trial presented at ASH 2017 did not demonstrate an improvement in the negative-PET rate after 2 cycles of brentuximab vedotin and AVD versus ABVD for patients with unfavorable-risk early-stage HL.

- a. True
- b. False

10. A study published in *Blood* by Moskowitz and colleagues demonstrated _____ baseline metabolic tumor volume to be a prognostic factor for favorable outcome.

- a. High
- b. Low